Structural insights into RAMP modification of secretin family G protein-coupled receptors: Implications for drug development

Trends in Pharmacological Sciences

Volumn 32, Issue 10, 2011, Pages 591-600

  Archbold, Julia K ^a,b   Flanagan, Jack U ^c,d   Watkins, Harriet A ^a   Gingell, Joseph J ^a,d   Hay, Debbie L ^a,d  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CORTICOTROPIN RELEASING FACTOR; EXENDIN 4; G PROTEIN COUPLED RECEPTOR; LIRAGLUTIDE; MK 2918; MK 3207; OLCEGEPANT; PARATHYROID HORMONE[1-34]; PEXACERFONT; PRAMLINTIDE; RECEPTOR ACTIVITY MODIFYING PROTEIN; RECEPTOR ACTIVITY MODIFYING PROTEIN 1; RECEPTOR ACTIVITY MODIFYING PROTEIN 2; RECEPTOR BLOCKING AGENT; RECOMBINANT GLUCAGON; RECOMBINANT PARATHYROID HORMONE; RG 1068; SALCATONIN; SECRETIN; TEDUGLUTIDE; TELCAGEPANT; TESAMORELIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANXIETY DISORDER; AUTISM; COMPLEX FORMATION; CROHN DISEASE; CRYSTAL STRUCTURE; DEPRESSION; DIABETES MELLITUS; DIMERIZATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; DWARFISM; HIV ASSOCIATED LIPODYSTROPHY; HORMONE BINDING; HORMONE PROTEIN COMPLEX; HUMAN; HYPOPARATHYROIDISM; IRRITABLE COLON; LIGAND BINDING; MIGRAINE; OBESITY; OLIGOMERIZATION; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MODIFICATION; RECEPTOR BLOCKING; REVIEW; SCHIZOPHRENIA; SHORT BOWEL SYNDROME; STRUCTURE ANALYSIS;

DRUG DESIGN; HUMANS; RECEPTOR ACTIVITY-MODIFYING PROTEINS; RECEPTORS, G-PROTEIN-COUPLED; SECRETIN;

EID: 80053374553     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2011.05.007     Document Type: Review

References (76)

1. J.P. Overington How many drug targets are there? Nat. Rev. Drug Discov. 5 2006 993 996 (Pubitemid 44835126)
2. R. Fredriksson The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints Mol. Pharmacol. 63 2003 1256 1272 (Pubitemid 36627220)
3. E.Y. Chien Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist Science 330 2010 1091 1095
4. V.P. Jaakola The 2.6 Angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist Science 322 2008 1211 1217
5. K. Palczewski Crystal structure of rhodopsin: a G protein-coupled receptor Science 289 2000 739 745 (Pubitemid 30650186)
6. J.H. Park Crystal structure of the ligand-free G-protein-coupled receptor opsin Nature 454 2008 183 187 (Pubitemid 351969893)
7. S.G. Rasmussen Crystal structure of the human beta2 adrenergic G-protein-coupled receptor Nature 450 2007 383 387 (Pubitemid 350126755)
8. D.M. Rosenbaum GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function Science 318 2007 1266 1273 (Pubitemid 350172885)
9. B. Wu Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists Science 330 2010 1066 1071
10. S.R. Hoare Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors Drug Discov. Today 10 2005 417 427 (Pubitemid 40450272)
11. C. Parthier Passing the baton in class B GPCRs: peptide hormone activation via helix induction? Trends Biochem. Sci. 34 2009 303 310
12. E. Ter Haar Crystal structure of the ectodomain complex of the CGRP receptor, a class-B GPCR, reveals the site of drug antagonism Structure 18 2010 1083 1093
13. C. Parthier Crystal structure of the incretin-bound extracellular domain of a G protein-coupled receptor Proc. Natl. Acad. Sci. U.S.A. 104 2007 13942 13947 (Pubitemid 350003317)
14. S. Runge Crystal structure of the ligand-bound glucagon-like peptide-1 receptor extracellular domain J. Biol. Chem. 283 2008 11340 11347
15. C.R. Underwood Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor J. Biol. Chem. 285 2010 723 730
16. A.A. Pioszak Dimeric arrangement of the parathyroid hormone receptor and a structural mechanism for ligand-induced dissociation J. Biol. Chem. 285 2010 12435 12444
17. A.A. Pioszak Molecular recognition of parathyroid hormone by its G protein-coupled receptor Proc. Natl. Acad. Sci. U.S.A. 105 2008 5034 5039 (Pubitemid 351738505)
18. C.R. Grace NMR structure of the first extracellular domain of corticotropin releasing factor receptor 1 (ECD1-CRF-R1) complexed with a high affinity agonist J. Biol. Chem. 285 2010 38580 38589
19. A.A. Pioszak Molecular recognition of corticotropin-releasing factor by its G-protein-coupled receptor CRFR1 J. Biol. Chem. 283 2008 32900 32912
20. K. Pal Structural basis for hormone recognition by the human CRFR2alpha G protein-coupled receptor J. Biol. Chem. 285 2010 40351 40361
21. 1H NMR and distance geometry with restrained molecular dynamics Biochemistry 30 1991 575 582
22. 1H-NMR study of the solution conformation of secretin. Resonance assignment and secondary structure FEBS Lett. 215 1987 88 94 (Pubitemid 17099144)
23. J.W. Neidigh Exendin-4 and glucagon-like-peptide-1: NMR structural comparisons in the solution and micelle-associated states Biochemistry 40 2001 13188 13200 (Pubitemid 33043533)
24. K. Ogawa Conformational analysis of human calcitonin in solution J. Pept. Sci. 12 2006 51 57 (Pubitemid 43033698)
25. 1H NMR and distance geometry with restrained molecular dynamics Protein Eng. 6 1993 149 156 (Pubitemid 23100794)
26. C.R. Grace NMR structure and peptide hormone binding site of the first extracellular domain of a type B1 G protein-coupled receptor Proc. Natl. Acad. Sci. U.S.A. 101 2004 12836 12841 (Pubitemid 39167545)
27. M.H. Perrin Distinct structural and functional roles of conserved residues in the first extracellular domain of receptors for corticotropin- releasing factor and related G-protein-coupled receptors J. Biol. Chem. 282 2007 37529 37536
28. C. Sun Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS Proc. Natl. Acad. Sci. U.S.A. 104 2007 7875 7880 (Pubitemid 47185844)
29. C. Rutz The corticotropin-releasing factor receptor type 2a contains an N-terminal pseudo signal peptide J. Biol. Chem. 281 2006 24910 24921 (Pubitemid 44274262)
30. J. Klose Impact of N-terminal domains for corticotropin-releasing factor (CRF) receptor-ligand interactions Biochemistry 44 2005 1614 1623 (Pubitemid 40207495)
31. S.L. Ritter Fine-tuning of GPCR activity by receptor-interacting proteins Nat. Rev. Mol. Cell Biol. 10 2009 819 830
32. J.P. Pin International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers Pharmacol. Rev. 59 2007 5 13
33. F. Gao Functional importance of a structurally distinct homodimeric complex of the family B G protein-coupled secretin receptor Mol. Pharmacol. 76 2009 264 274
34. K.G. Harikumar Importance of lipid-exposed residues in transmembrane segment four for family B calcitonin receptor homo-dimerization Regul. Pept. 164 2010 113 119
35. K.G. Harikumar Dimerization in the absence of higher-order oligomerization of the G protein-coupled secretin receptor Biochim. Biophys. Acta 1778 2008 2555 2563
36. K.G. Harikumar Constitutive formation of oligomeric complexes between family B G protein-coupled vasoactive intestinal polypeptide and secretin receptors Mol. Pharmacol. 69 2006 363 373 (Pubitemid 43048923)
37. K.G. Harikumar Pattern of intra-family hetero-oligomerization involving the G-protein-coupled secretin receptor J. Mol. Neurosci. 36 2008 279 285
38. K.G. Harikumar Transmembrane segment IV contributes a functionally important interface for oligomerization of the Class II G protein-coupled secretin receptor J. Biol. Chem. 282 2007 30363 30372 (Pubitemid 350035177)
39. M. Heroux Functional calcitonin gene-related peptide receptors are formed by the asymmetric assembly of a calcitonin receptor-like receptor homo-oligomer and a monomer of receptor activity-modifying protein-1 J. Biol. Chem. 282 2007 31610 31620 (Pubitemid 350044900)
40. O. Kraetke Dimerization of corticotropin-releasing factor receptor type 1 is not coupled to ligand binding J. Recept. Signal Transduct. Res. 25 2005 251 276 (Pubitemid 43068279)
41. C.S. Lisenbee Secretin receptor oligomers form intracellularly during maturation through receptor core domains Biochemistry 45 2006 8216 8226 (Pubitemid 44036527)
42. A. Christopoulos Novel receptor partners and function of receptor activity-modifying proteins J. Biol. Chem. 278 2003 3293 3297 (Pubitemid 36801242)
43. K.G. Harikumar Molecular basis of association of receptor activity-modifying protein 3 with the family B G protein-coupled secretin receptor Biochemistry 48 2009 11773 11785
44. P.M. Sexton Complexing receptor pharmacology: modulation of family B G protein-coupled receptor function by RAMPs Ann. N. Y. Acad. Sci. 1070 2006 90 104 (Pubitemid 44126627)
45. P.M. Sexton Modulating receptor function through RAMPs: can they represent drug targets in themselves? Drug Discov. Today 14 2009 413 419
46. T. Qi Structure-function relationships of the N-terminus of receptor activity-modifying proteins Br. J. Pharmacol. 159 2009 1059 1068
47. S. Kusano Crystal structure of the human receptor activity-modifying protein 1 extracellular domain Protein Sci. 17 2008 1907 1914
48. S. Hilairet Agonist-promoted internalization of a ternary complex between calcitonin receptor-like receptor, receptor activity-modifying protein 1 (RAMP1), and beta-arrestin J. Biol. Chem. 276 2001 42182 42190
49. S. Hilairet Protein-protein interaction and not glycosylation determines the binding selectivity of heterodimers between the calcitonin receptor-like receptor and the receptor activity-modifying proteins J. Biol. Chem. 276 2001 29575 29581
50. T. Qi Structure-function analysis of RAMP1-RAMP3 chimeras Biochemistry 49 2009 522 531
51. J. Simms Structure-function analysis of RAMP1 by alanine mutagenesis Biochemistry 48 2009 198 205
52. T. Qi Identification of N-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and amylin receptor function Mol. Pharmacol. 74 2008 1059 1071
53. J. Barwell Mapping interaction sites within the N-terminus of the calcitonin gene-related peptide receptor; the role of residues 23-60 of the calcitonin receptor-like receptor Peptides 31 2009 170 176
54. S. Banerjee Identification of specific calcitonin-like receptor residues important for calcitonin gene-related peptide high affinity binding BMC Pharmacol. 6 2006 9
55. E.L. Moore Mapping the CGRP receptor ligand binding domain: tryptophan-84 of RAMP1 is critical for agonist and antagonist binding Biochem. Biophys. Res. Commun. 394 2010 141 145
56. T. Qi Structure-function analysis of amino acid 74 of human RAMP1 and RAMP3 and its role in peptide interactions with adrenomedullin and calcitonin gene-related peptide receptors Peptides 32 2011 1060 1067
57. D.L. Hay Determinants of 1-piperidinecarboxamide, N-[2-[[5-amino-l-[[4- (4-pyridinyl)-l-piperazinyl]carbonyl]pentyl]amino]-1-[(3,5-dibromo-4- hydroxyphenyl)methyl]-2-oxoethyl]-4-(1,4-dihydro-2-oxo-3(2H)-quinazolinyl) (BIBN4096BS) affinity for calcitonin gene-related peptide and amylin receptors - the role of receptor activity modifying protein 1 Mol. Pharmacol. 70 2006 1984 1991 (Pubitemid 44771914)
58. M.J.M. Fischer Calcitonin gene-related peptide receptor antagonists for migraine Expert Opin. Investig. Drugs 19 2010 815 823
59. K. Rudolf Development of human calcitonin gene-related peptide (CGRP) receptor antagonists. 1. Potent and selective small molecule CGRP antagonists. 1-[N2-[3,5-dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1- piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine: the first CGRP antagonist for clinical trials in acute migraine J. Med. Chem. 48 2005 5921 5931 (Pubitemid 41324603)
60. T.M. Williams Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead Bioorg. Med. Chem. Lett. 16 2006 2595 2598
61. D.V. Paone Calcitonin gene-related peptide receptor antagonists for the treatment of migraine: a patent review Expert Opin. Ther. Patents 19 2009 1675 1713
62. C.S. Burgey Benzodiazepine calcitonin gene-related peptide (CGRP) receptor antagonists: optimization of the 4-substituted piperidine Bioorg. Med. Chem. Lett. 16 2006 5052 5056 (Pubitemid 44247711)
63. I.M. Bell Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists Bioorg. Med. Chem. Lett. 16 2006 6165 6169 (Pubitemid 44709924)
64. I.M. Bell Discovery of MK-3207: a highly potent, orally bioavailable CGRP receptor antagonist ACS Med. Chem. Lett. 1 2010 24 29
65. D.V. Paone Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: discovery of MK-2918 Bioorg. Med. Chem. Lett. 21 2011 2683 2686
66. A.W. Shaw Caprolactams as potent CGRP receptor antagonists for the treatment of migraine Bioorg. Med. Chem. Lett. 17 2007 4795 4798 (Pubitemid 47187710)
67. D.N. Nguyen Calcitonin gene-related peptide (CGRP) receptor antagonists: investigations of a pyridinone template Bioorg. Med. Chem. Lett. 18 2008 755 758
68. D.L. Hay GPCR modulation by RAMPs Pharmacol. Ther. 109 2006 173 197 (Pubitemid 41740820)
69. J.J. Mallee Receptor activity-modifying protein 1 determines the species selectivity of non-peptide CGRP receptor antagonists J. Biol. Chem. 277 2002 14294 14298 (Pubitemid 34968045)
70. C.A. Salvatore Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl] -4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine J. Pharmacol. Exp. Ther. 324 2008 416 421 (Pubitemid 351185864)
71. C.A. Salvatore Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist J. Pharmacol. Exp. Ther. 333 2010 152 160
72. P.S Miller Non-peptidic antagonists of the CGRP receptor, BIBN4096BS and MK-0974, interact with the calcitonin receptor-like receptor via methionine-42 and RAMP1 via tryptophan-74 Biochem. Biophys. Res. Commun. 391 2010 437 442
73. K. Bellmann-Sickert Peptide drugs to target G protein-coupled receptors Trends Pharmacol. Sci. 31 2010 434 441
74. L. Dickson VPAC and PAC receptors: from ligands to function Pharmacol. Ther. 121 2009 294 316
75. S.M. Foord International Union of Pharmacology. XLVI. G protein-coupled receptor list Pharmacol. Rev. 57 2005 279 288 (Pubitemid 41043887)
76. A.J. Harmar Family-B G-protein-coupled receptors Genome Biol. 2 2001 1 10 Review S3013